Purpose: This is an internally-controlled study designed to demonstrate how to best begin 3,4-diaminopyridine (DAP) treatment in patients with Lambert-Eaton Syndrome (LEMS) and how to assess the continuing need for and optimal dose of DAP in these patients. DAP is an orphan drug that has been used elsewhere in the world for over 20 years to improve strength in patients with LEMS, myasthenia gravis (MG), and congenital myasthenia syndromes. In many countries it is considered standard therapy for LEMS. The study will determine the initial dose of DAP, will validate several clinical instruments used to assess patient response to DAP, and will develop a protocol to assess patients' continuing need for DAP. Methods: Each patient serves as his/her own control. Ten patients with LEMS are being followed in the Duke Neuromuscular Clinic and who have been taking a stable dose of DAP and pyridostigmine for at least one month will be asked to participate. Patients will be hospitalized for this study for 2 weeks on the Duke GCRC. They will discontinue DAP for 2 days, and then take three different doses on 3 consecutive days. The dose which produces the best improvement in strength will then be given three times a day for 2 days. DAP will then be stopped for 2 days, and then the same dose will be given for another 2 days. Results: One patient with LEMS completed the protocol. There were no adverse events. All 3 criteria for a successful outcome of the primary objective were met, and the secondary objectives were informative. The protocol predicted the best starting dose and indicated that the patient had been taking the most appropriate dose of 3,4-diaminopyridine. This study was planned to include a total of ten patients, however, because of lack of funding, it has been cancelled.
| Askie, Lisa M; Darlow, Brian A; Finer, Neil et al. (2018) Association Between Oxygen Saturation Targeting and Death or Disability in Extremely Preterm Infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration. JAMA 319:2190-2201 |
| Srinivasan, Lakshmi; Page, Grier; Kirpalani, Haresh et al. (2017) Genome-wide association study of sepsis in extremely premature infants. Arch Dis Child Fetal Neonatal Ed 102:F439-F445 |
| Denson, Lee A; McDonald, Scott A; Das, Abhik et al. (2017) Early Elevation in Interleukin-6 is Associated with Reduced Growth in Extremely Low Birth Weight Infants. Am J Perinatol 34:240-247 |
| James, Jennifer; Munson, David; DeMauro, Sara B et al. (2017) Outcomes of Preterm Infants following Discussions about Withdrawal or Withholding of Life Support. J Pediatr 190:118-123.e4 |
| Younge, Noelle; Goldstein, Ricki F; Bann, Carla M et al. (2017) Survival and Neurodevelopmental Outcomes among Periviable Infants. N Engl J Med 376:617-628 |
| Archer, Stephanie Wilson; Carlo, Waldemar A; Truog, William E et al. (2016) Improving publication rates in a collaborative clinical trials research network. Semin Perinatol 40:410-417 |
| Ahmed, Zuhayer; Prasad, Indrajit; Rahman, Hafizur et al. (2016) A Male with Extreme Subcutaneous Insulin Resistance: A Case Report. Rom J Diabetes Nutr Metab Dis 23:209-213 |
| Phelps, Dale L; Ward, Robert M; Williams, Rick L et al. (2016) Safety and pharmacokinetics of multiple dose myo-inositol in preterm infants. Pediatr Res 80:209-17 |
| Barroso, Julie; Leserman, Jane; Harmon, James L et al. (2015) Fatigue in HIV-Infected People: A Three-Year Observational Study. J Pain Symptom Manage 50:69-79 |
| Stafford-Smith, Mark; Li, Yi-Ju; Mathew, Joseph P et al. (2015) Genome-wide association study of acute kidney injury after coronary bypass graft surgery identifies susceptibility loci. Kidney Int 88:823-32 |
Showing the most recent 10 out of 128 publications
